Table 3.

Summary of T-Cell ELISpot response.

	High-Dose (n = 12)	Low-Dose (n = 11)	Placebo (n = 6)	p-Value 1+	p-Value 2+	p-Value 3+	p-Value 4
Day 0 (pre-dose)	0 (0–3.8)	10 (0–15)	2.5 (0–63.8)	0.09	0.46	0.10	0.29
Day 7	10 (0–42.5)	15 (5–20)	22.5 (8.8–43.8)	0.23	0.17	0.03	0.45
Day 14	15 (0–31.3)	0 (0–5)	0 (0–10)	0.17	0.16	0.09	0.52
Day 28 (pre-dose)	27.5 (6.3–130)	25 (0–30)	72.5 (13.8–132.5)	0.55	0.08	0.29	0.43
Day 35	20 (5–48.8)	15 (5–30)	20 (8.75–37.5)	0.19	0.38	0.55	0.80
Day 42	12.5 (5–52.5)	0 (0–40)	5 (0–27.5)	0.18	0.19	0.09	0.49

High-dose: DelNS1-nCoV-RBD LAIV (1 × 10^7.7 EID₅₀/dose) in 0.2 mL. Low-dose: DelNS1-nCoV-RBD LAIV (1 × 10⁷ EID₅₀/dose) in 0.2 mL. Placebo: inert excipients/ dose in 0.2 mL. p-value ¹: High-dose vs. Placebo. p-value ²: Low-dose vs. Placebo. p-value ³: High-dose vs. Low-dose. + Mann-Whitney U test. p-value ⁴: one-way ANOVA, comparison of three groups. data were median SFU/10⁶ PBMC (IQR).